Frequent amplification of receptor tyrosine kinase genes in well-differentiated/ dedifferentiated liposarcoma-Reference-Cited by-同舟云学术

Frequent amplification of receptor tyrosine kinase genes in well-differentiated/ dedifferentiated liposarcoma

Published:2017-01-14 Issue:8 Volume:8 Page:12941-12952
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Asano Naofumi¹²,Yoshida Akihiko³,Mitani Sachiyo⁴,Kobayashi Eisuke⁵,Shiotani Bunsyo⁶,Komiyama Motokiyo⁷,Fujimoto Hiroyuki⁷,Chuman Hirokazu⁵,Morioka Hideo²,Matsumoto Morio²,Nakamura Masaya²,Kubo Takashi⁸,Kato Mamoru⁹,Kohno Takashi⁸¹⁰,Kawai Akira⁵,Kondo Tadashi¹,Ichikawa Hitoshi⁴⁸

Affiliation:

1. Division of Rare Cancer Research, National Cancer Center Research Institute, Chuo-ku, Tokyo 104-0045, Japan

2. Department of Orthopaedic Surgery, Keio University School of Medicine, Shinjuku-ku, Tokyo 160-8582, Japan

3. Department of Pathology and Clinical Laboratory, National Cancer Center Hospital, Chuo-ku, Tokyo 104-0045, Japan

4. Department of Clinical Genomics, National Cancer Center Research Institute, Chuo-ku, Tokyo 104-0045, Japan

5. Department of Musculoskeletal Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo 104-0045, Japan

6. Division of Genetics, National Cancer Center Research Institute, Chuo-ku, Tokyo 104-0045, Japan

7. Department of Urology, National Cancer Center Hospital, Chuo-ku, Tokyo 104-0045, Japan

8. Division of Translational Genomics, National Cancer Center-Exploratory Oncology Research and Clinical Trial Center, Chuo-ku, Tokyo 104-0045, Japan

9. Department of Bioinformatics, National Cancer Center Research Institute, Chuo-ku, Tokyo 104-0045, Japan

10. Division of Genome Biology, National Cancer Center Research Institute, Chuo-ku, Tokyo 104-0045, Japan

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current unmet needs in locally advanced (unresectable) or metastatic dedifferentiated liposarcoma, the relevance of progression-free survival as clinical endpoint, and expectations for future clinical trial design: an international Delphi consensus report;ESMO Open;2024-07

2. HER3 (ERBB3) amplification in liposarcoma - a putative new therapeutic target?;World Journal of Surgical Oncology;2024-05-17

3. Biology and Management of Deep-seated Atypical Lipomatous Tumor of the Extremities;Anticancer Research;2023-09-29

4. The MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study;Cancer Discovery;2023-06-03

5. A Single-Arm Phase II Trial of Sitravatinib in Advanced Well-Differentiated/Dedifferentiated Liposarcoma;Clinical Cancer Research;2022-12-22